Lake Street raised the firm's price target on P3 Health Partners to $14 from $4 and keeps a Buy rating on the shares. The transitional year of 2025 is "finally over" and 2026 is "off to an auspicious start" with the conversion of debt to equity and a shored-up balance sheet, the analyst tells investors. While it may take a couple more quarters for sentiment to fully shift, the firm thinks "the possibility for substantial upside and meaningful multiple expansion is more assured today than it has been in years," the analyst added.
